Incompatible Live-Donor Kidney Transplantation in the United States: Results of a National Survey
|
|
- Evan Robinson
- 5 years ago
- Views:
Transcription
1 Article Incompatible Live-Donor Kidney Transplantation in the United States: Results of a National Survey Jacqueline M. Garonzik Wang,* Robert A. Montgomery,* Lauren M. Kucirka,* Jonathan C. Berger,* Daniel S. Warren,* and Dorry L. Segev* Summary Background and objectives Use of incompatible kidney transplantation (IKT) is growing as a response to the organ shortage and the increase in sensitization among candidates. However, recent regulatory mandates possibly threaten IKT, and the potential effect of these mandates cannot be estimated because dissemination of this modality remains unknown. The goal of this study was to better understand practice patterns of IKT in the United States. Design, setting, participants, & measurements Directors from all 187 unique active adult kidney transplant programs were queried about transplantation across the following antibody barriers: positive Luminex, negative flow crossmatch (PLNF); positive flow, negative cytotoxic crossmatch (PFNC); positive cytotoxic crossmatch (PCC); and ABO incompatible (ABOi). Results Responses from 125 centers represented 84% of the live-donor transplant volume in the United States. Barriers of PLNF, PFNC, PCC, and ABOi are being crossed in 70%, 51%, 18%, and 24%, respectively, of transplant centers that responded. Desensitization was performed in 58% of PLNF, 76% of PFNC, 100% of PCC, and 80% of ABOi using plasmapheresis and low-dose intravenous Ig (IVIg) in 71% to 83% and high-dose IVIg in 29% to 46%. Conclusions A higher proportion of centers perform IKT than might be inferred from the literature. The rapid dissemination of these protocols despite adequate evidence of a clear advantage of IKT transplants argues for the creation of a national registry and randomized studies. Clin J Am Soc Nephrol 6: , doi: /CJN *Department of Surgery, Johns Hopkins University School of Medicine, and Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland Correspondence: Dr. Dorry Segev, Transplant Surgery, Johns Hopkins Medical Institutions, 720 Rutland Avenue, Ross 771B, Baltimore, MD Phone: ; Fax: ; dorry@jhmi.edu Introduction Live kidney donation is safe and offers the recipient the best chances for survival, yet it is estimated that thousands of patients with kidney failure are relegated to the deceased-donor waiting list because of HLA or ABO incompatibilities even with a healthy, willing live donor (1 4). In an effort to transplant these patients, centers are increasingly turning to creative modalities such as incompatible kidney transplantation (IKT) with desensitization, kidney paired donation (KPD), or list paired donation (LPD). Advances in immunosuppression, desensitization, and KPD have enabled some centers across the country and throughout the world to transplant across immunologic barriers (5 17). We define IKT as live-donor kidney transplantation with known donor-specific antibody (DSA). Despite what appear to be growing IKT practices, there is currently no systematic nationwide method of collecting data on the use of this modality or its associated outcomes. Therefore, all inferences about IKT dissemination are limited by publication bias, with reports from only a handful of relatively high-volume centers. Because of limited knowledge about IKT practices or outcomes in the United States, relevant factors are not currently accounted for in the Scientific Registry of Transplant Recipients (SRTR) risk adjustment models. Specifically, current SRTR models do not adjust for transplantation against HLA or ABO barriers, and they do not account for desensitization practices. Although they adjust for panel reactive antibody (PRA), this metric accounts for breadth of sensitization rather than the strength of antibody specifically against a donor. In attempt to better understand the use of IKT in the United States, we surveyed directors from all active adult kidney transplant programs. We asked detailed questions about transplantation across immunologic barriers and desensitization practices including the use of immunosuppressive regimens, plasmapheresis, and rituximab. The goals of this study were to characterize national IKT practices as a first step toward improved reporting of outcomes and further standardization of protocols and best practices. Materials and Methods Using publically available data, we identified 196 transplant centers within the United States that per- Vol 6 August, 2011 Copyright 2011 by the American Society of Nephrology 2041
2 2042 Clinical Journal of the American Society of Nephrology formed at least one adult ( 18 years) live-donor kidney transplant in 2008 or These centers were contacted via phone to obtain the identity and contact information of their current kidney transplant director, defined as the person listed with the United Network for Organ Sharing as the primary responsible transplant surgeon. If multiple centers in one geographic location shared a director, we combined those into one center so that the director would only complete one survey. Of the resulting 187 centers, we then contacted each director via and provided a link to an online electronic survey using Survey Monkey ( We also provided a hard copy of the survey if requested, of which 17 were returned and included in the study. If the director whom we initially contacted believed that a different faculty member was a more appropriate respondent (for example, a nephrologist or transplant surgeon who directed the IKT program at a given center), we contacted the alternative person provided. Two response rates are reported. First, we report the absolute proportion of centers that returned our survey; in other words, the number of responses divided by 187. Second, we report the proportion of live-donor kidney transplant volume represented by our responses. For this estimate, we summed the number of live-donor transplants performed in 2008 at the centers that completed our survey and divided this sum by the total number of livedonor transplants performed in the United States in that year. Respondents were asked if their centers performed any of the following types of incompatible kidney transplants: transplants with evidence of DSA by Luminex, but with negative flow cytometric crossmatch (PLNF); transplants with positive flow cytometric crossmatch, but negative cytotoxic crossmatch (PFNC); transplants with positive cytotoxic crossmatch (PCC); and transplants that were ABO incompatible (ABOi). Respondents were also asked if desensitization was used at their center for each of the above incompatibilities and, if so, they were asked to describe their desensitization protocols. Specific questions were asked about the use of plasmapheresis and low-dose intravenous Ig (PP/IVIg), high-dose intravenous Ig (IVIg), and pretransplant anti-cd20 antibody (rituximab). Finally, centers were questioned about what assays they used to determine levels of incompatibility and what titers they considered safe to proceed with transplantation. The estimated prevalence of IKT use is reported as the proportion of respondents reporting transplantation across a given IKT barrier. However, although response rates were high (67%), responses were clearly not obtained from all eligible transplant centers. Two assumptions (at opposite extremes) were used to inform the possible range of prevalence estimates. One assumption was that centers not responding to the study simply did not perform IKT and as such either (1) had no interest in the study or (2) assumed that responding would be noninformative. Under this assumption, the lower bound of a prevalence estimate was determined as the number of centers performing IKT divided by the total number of eligible centers that were contacted. The other extreme assumption, albeit far less likely, was that all centers not responding to the study did indeed perform IKT, so the upper bound of a prevalence estimate was determined as the number of centers reporting that they performed IKT plus the number of nonresponders, all divided by the total number of eligible centers. Statistical analysis was performed using Stata 11/MP for Windows (Stata Corporation, College Station, TX). Results Performance of Incompatible Kidney Transplants Responses were obtained from 125 centers, representing 67% of kidney transplant centers and 84% of the volume of live-donor kidney transplants in the United States. Ninetythree centers (74% of respondents, possible range 50% to 83% of US centers) performed at least one kind of IKT. Eighty-six centers (70%, possible range 46% to 80%) performed kidney transplants with PLNF. This type of incompatibility was the most widely disseminated (Figure 1). Sixty-three centers (51%, possible range 34% to 69%) performed IKTs with a PFNC, 22 centers (18%, possible range 12% to 46%) performed kidney transplants with PCC, and 30 centers (24%, possible range 16% to 50%) performed ABOi kidney transplants. Use of Desensitization/Preconditioning Use of desensitization varied across the four types of incompatibility (Table 1). Fifty-eight percent of centers performing PLNF reported desensitizing these patients, compared with 76% of centers performing PFNC and 100% of centers performing PCC. Among centers desensitizing for HLA barriers (PLNF, PFNC, and PCC), all centers indicated at least one specific modality (PP/IVIg, IVIg, or other) and approximately 35% to 40% indicated using more than one modality; 71% to 82% reported using PP/ IVIg, 36% to 46% using IVIg, and 23% to 29% using other modalities. Among centers performing ABOi transplants, Figure 1. Proportion of transplant centers in the United States performing incompatible kidney transplants by level of incompatibility. The upper and lower bounds represent the percentages of centers performing each type of transplant had all of the nonrespondents performed that type of transplant (upper bounds, Max % ) or had all nonrespondents not performed that type of transplant (lower bounds, Min % ). The central dot represents the observed percentage of respondents that performed that type of transplant. PLNF, positive Luminex DSA/negative flow cytometric crossmatch; PFNC, positive flow cytometric crossmatch/negative cytotoxic crossmatch; PCC, positive cytotoxic crossmatch; ABOi, ABO incompatible.
3 Clin J Am Soc Nephrol 6: , August, 2011 Incompatible Live-Donor Transplantation in United States, Segev et al Table 1. Types of desensitization performed in the United States by type of incompatibility Type Performed? a Desensitize? b PP/IVIg c IVIg c Other c CD20 d PLNF 86/123 50/86 37/50 23/50 14/50 27/49 (70%) (58%) (74%) (46%) (28%) (55%) PFNC 63/123 48/63 34/48 21/48 14/48 25/47 (51%) (76%) (71%) (44%) (29%) (53%) PCC 22/123 22/22 18/22 8/22 5/22 13/22 (18%) (100%) (82%) (36%) (23%) (59%) ABOi 30/124 24/30 20/24 7/24 7/24 16/26 (24%) (80%) e (83%) (29%) (29%) (62%) PP/IVIg, plasmapheresis and low-dose intravenous Ig; IVIg, high-dose intravenous Ig; PLNF, positive Luminex, negative flow crossmatch; PFNC, positive flow, negative cytotoxic crossmatch; PCC, positive cytotoxic crossmatch; ABOi, ABO incompatible. a Numbers represent the percent on the basis of those from the overall cohort who answered the given question. For example, there were 86 centers that performed PLNF transplants, representing 70% of the 123 centers that responded to the set of questions about PLNF transplants. b Numbers represent the percent on the basis of those who reported performing the given modality. For example, of those 86 centers that performed PLNF transplants, 50 of 86 (58%) used preoperative desensitization in that situation. c Numbers represent the percent on the basis of those who reported using desensitization. For example, of those 50 centers that desensitized PLNF recipients, 37 (74%) used PP/IVIg. d Numbers represent the percent on the basis of those who answered the question about anti-cd20 antibody. For example, of 49 centers reporting use of anti-cd20, 27 stated that they never used it in PLNF situations. e For ABOi transplants, the number represents those who precondition with A2, B, or A1 donors. Of 30 centers that performed ABOi transplants, 24 (80%) precondition one of those blood type donors and 15 (50%, not shown in table) reported always preconditioning for ABOi transplants. 50% reported always preconditioning these recipients; with regards to specific donor blood types, 60% reported preconditioning patients with A2 donors, 60% with B donors, and 63% with A1 donors, with 80% of centers reporting preconditioning at least one of these blood types. For ABOi transplants, of those preconditioning recipients, 83% reported using PP/IVIg, 29% using IVIg, and 29% using other modalities. Use of Pretransplant Anti-CD20 Antibody More than half of all centers (55% for PLNF, 53% for PFNC, 59% for PCC, and 62% for ABOi) reported giving preoperative rituximab (Table 1). Of the centers that reported using rituximab, 45 provided more detail regarding their dosing regimen. Most of these centers reported using 375 mg/m 2, but doses ranged from 150 mg to 1 g. DSA Testing We asked centers to further define their methods of antibody testing. Of the 46 centers that routinely desensitized PFNC patients and answered this question (four centers did not answer the question), 44 (96%) routinely tested for the presence of DSA. All 21 centers performing PCC who answered this question (one center did not answer the question) routinely confirmed the presence of DSA. Testing modalities of choice included Luminex testing, Labscreen, flow cytometric crossmatch, and other cellbased modalities. One center reported using the novel c1q assay created at Stanford University. Thresholds for a positive test varied from 300 to 3000 median fluorescent intensity for Luminex testing and from 10 to 60 mean channel shifts for flow cytometry. Similarly, strength of reactivity considered too high to initiate desensitization varied from a complement-dependent cytotoxicity (CDC) titer of 1:8 to 1:512. ABO testing modalities included tubetest anti-human globulin, saline drop tube method, isohemagglutinins, Coombs, agglutination with two-tube dilution, and gel card direct tube test. Titers considered too high to initiate preconditioning for ABOi varied from 1:8 to 1:2048. We caution that although these responses provide a sense of the breadth of testing modalities used in IKT centers, these were free-response questions that do not lend themselves to quantifying the use of these various modalities. Discussion In this national survey of kidney transplant centers, with responses representing 84% of the live-donor kidney transplant volume in the United States, wide dissemination of incompatible kidney transplant practices was found. Of respondents, 74% reported performing at least one type of IKT (indicating a national range of 50% to 83%), with 70% (46% to 80%) crossing PLNF, 51% (34% to 69%) crossing PFNC, 18% (12% to 46%) crossing PCC, and 24% (16% to 50%) crossing ABO barriers. Desensitization was used by most centers crossing any of these barriers, with most reporting the use of PP/IVIg and approximately one half of centers using anti-cd20 antibody. However, not all centers used desensitization for lower strength antibody, with only 58% using desensitization for PLNF and 76% for PFNC; variations in immunosuppression (such as use of antithymocyte globulin) were not queried. Donor-specific or ABO antibody testing varied widely. This survey represents a first step in cataloging current practices in managing anti-hla and ABO antibody at centers throughout the United States. Much more detailed analysis of phenotypes, protocols, and outcomes will be needed to obtain an accurate picture of this emerging field.
4 2044 Clinical Journal of the American Society of Nephrology The survey attempts to address the problem of the wide variability in the DSA strength among patients undergoing desensitization by defining three categories of antibody reactivity and the existing practice patterns associated with each category. This includes characterizing center-specific assessment of the need for desensitization associated with varying degrees of antibody strength in addition to willingness to transplant these patients. Although cutoffs for these three categories vary somewhat, a correlation has been consistently shown among escalating antibody levels, antibody-mediated rejection (AMR), and graft loss among patients undergoing desensitization (18). Even low levels of DSA have been associated with the development of posttransplant AMR and poorer outcomes (19). Although there appears to be widespread practice of IKT throughout the United States, the utility and efficacy of desensitization for DSA remains largely anecdotal and unproven (20). Only a few randomized trials have been published, showing a modest improvement in outcomes, PRA reduction, or transplant rate with high-dose IVIg (21,22). There are also numerous small single-center series showing good short-term outcomes after desensitization with high-dose IVIg or PP/IVIg, although rates of AMR and graft loss are higher than for transplants among unsensitized patients (5,6,8,23). Vo et al. used high-dose IVIg and anti-cd20 to desensitize 20 patients and achieved an 80% transplant rate and a 94% graft survival rate 12 months after treatment and transplant, respectively (8). These studies have many limitations, including variable antibody testing techniques, patient populations, phenotypes, and treatment protocols as well as inconsistencies related to the definitions of sensitization and response to therapy. There are very limited long-term outcome data on transplantation after desensitization. A report by Haririan et al. found that 14 patients desensitized for a positive flow crossmatch with 5 years of follow-up had a graft survival of 69.4% (24). HLA sensitization affects 30% of the patients on the kidney deceased-donor waiting list. More than 8000 registrants are highly sensitized (PRA 80%). Annual transplant rates for highly sensitized patients are as low as 6.5% (8). For most highly sensitized patients there are two options: remain on dialysis or undergo desensitization. On average, patients who undergo compatible transplantation live twice as long as patients who remain on dialysis (4). For those patients who have willing but HLA-incompatible donors, KPD offers the possibility of finding a compatible live donor. Unfortunately, KPD opportunities for highly sensitized patients are quite limited (2). Given the current options, desensitization may provide the best outcome, quality of life, and health care savings for many sensitized patients (2). However, better long-term outcomes data and prospective studies are necessary to definitively demonstrate an advantage to this therapy. On the other hand, the results of ABOi transplants appear to be better than those of HLA-incompatible transplants. Our group recently reported 1-, 3-, and 5-year ABOi graft survival rates of 98.3%, 92.9%, and 88.7%, respectively, which are comparable to United Network for Organ Sharing data for compatible live-donor kidney transplants (9). This can be achieved with only a brief escalation in immunosuppression and without long-term B cell suppression from splenectomy or anti-cd20. Groups from Japan and Sweden have published very similar results (25,26). In the survey presented here, fewer centers reported transplantation across ABO barriers than desensitization for HLA antibody, and it remains unclear whether these excellent results from very specialized centers will be maintained when the techniques become more widely disseminated. It is likely that outcomes of IKT will be inferior to those of compatible transplants because of a combination of (1) the immunologic risk inherent to the incompatibility, (2) the risks of the actual desensitization procedure, and (3) latent factors (such as increased comorbidity) associated with the highly sensitized recipient population. Current regulatory and quality assurance paradigms do not account for the use of this modality among centers performing these specialized transplants. Regulatory agencies use SRTR multivariate regression models for risk adjustment, and expected survival is calculated by mathematical formula on the basis of the estimated effect of several donor and recipient factors on transplant outcomes. The expected survival calculated by these models is likely not an accurate estimate for the outlying IKT population. Centers offering desensitization to a large enough cohort of patients are likely to experience reduced patient and graft survival rates, which could trigger regulatory action. Regulatory pressures may inhibit the development of larger, better trials that are necessary to answer important questions and compare the effectiveness of different desensitization protocols. Similarly, costs and insurance reimbursement for these procedures may also represent disincentives. We acknowledge that registry-based risk prediction for IKT will be imperfect and limited by misclassification. Indeed, we found that cutoffs for PLNF and PFNC vary between centers. However, it is likely that even a simple adjustment (for example, any patient who has undergone pretransplant desensitization) will capture a high proportion of the explanatory power associated with IKT. The remaining nuances will have to be determined later. However, we point out that this kind of misclassification and imperfection associated with registry-based risk prediction already exists in the current transplant outcomes models. For example, diabetes is treated as a binary variable in which the spectrum of diabetes as it pertains to risk (age of onset, duration of disease, glucose control, sequelae) is likely just as wide, or perhaps even wider, than the spectrum of IKT as it pertains to risk. Several limitations of this survey merit discussion. First, our response rate was 67%; although this is a very high response rate for a survey study, and although our respondents represented 84% of the volume of live-donor kidney transplants in the United States, any response rate 100% makes prevalence estimates challenging. We have addressed this limitation by providing a range that is based on upper and lower bounds sensitivity analyses whenever prevalence estimates were provided. Because some centers do not even test using Luminex, and as such might unknowingly be transplanting patients with low levels of DSA, we might be underestimating the proportion of centers performing PLNF transplants. Our inferences are also
5 Clin J Am Soc Nephrol 6: , August, 2011 Incompatible Live-Donor Transplantation in United States, Segev et al limited by the binary nature of our study questions: We asked providers to indicate if they did or did not perform a certain type of IKT, but not how many of these cases were performed. We made this choice purposefully, under the likely assumption that estimating the number of cases that a center performed without actually enumerating these cases would be highly unreliable, particularly in light of the wide variation in what centers actually defined to be IKT. We hope that a future study in which IKT recipients are actually enumerated and studied in multiple centers will better inform this research question. Finally, the nuances of each center s IKT practice (e.g., details of rituximab dosing and details of DSA testing) were obtained only through open-ended questions, limiting our inferences at this level to qualitative ones. In conclusion, we have shown that a higher proportion of transplant centers perform IKT than might be inferred from the literature. Future research should be focused on developing a national IKT registry and capturing data that are not currently being reported. From these data, appropriate risk adjustment models and novel approaches to quality assurance and outcome evaluation can be developed. Most importantly, there is a need for multicenter randomized trials to establish best practices and to assess the effectiveness of desensitization in offering a survival benefit to sensitized patients. Acknowledgments We very much appreciate the time and effort of each of the 125 physicians who participated in this study. Without them these findings would not have been possible. Support was provided by a grant (RC1 DK086731) from the National Institute of Diabetes and Digestive and Kidney Diseases (D.L.S., D.S.W., R.A.M.) with additional funding from the Charles T. Bauer Foundation (R.A.M. and D.S.W.). This work was presented at the American Transplant Congress, May 1 5, 2010, San Diego, California. Disclosures None. References 1. Gentry SE, Segev DL, Montgomery RA: A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 5: , Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA: Kidney paired donation and optimizing the use of live donor organs. JAMA 293: , Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, McBride MA, Montgomery RA: Perioperative mortality and long-term survival following live kidney donation. JAMA 303: , Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: , Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE: Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70: , Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, Leffell MS: Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76: , Glotz D, Antoine C, Julia P, Pegaz-Fiornet B, Duboust A, Boudjeltia S, Fraoui R, Combes M, Bariety J: Intravenous immunoglobulins and transplantation for patients with anti-hla antibodies. Transpl Int 17: 1 8, Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: , Montgomery RA, Locke JE, King KE, Segev DL, Warren DS, Kraus ES, Cooper M, Simpkins CE, Singer AL, Stewart ZA, Melancon JK, Ratner L, Zachary AA, Haas M: ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 87: , Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, Grande JP, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Velosa JA, Textor SC, Platt JL, Stegall MD: ABO-incompatible kidney transplantation using both A2 and non-a2 living donors. Transplantation 75: , Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y: Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4: , Segev DL, Simpkins CE, Warren DS, King KE, Shirey RS, Maley WR, Melancon JK, Cooper M, Kozlowski T, Montgomery RA: ABO incompatible high-titer renal transplantation without splenectomy or anti-cd20 treatment. Am J Transplant 5: , Montgomery RA, Zachary AA, Ratner LE, Segev DL, Hiller JM, Houp J, Cooper M, Kavoussi L, Jarrett T, Burdick J, Maley WR, Melancon JK, Kozlowski T, Simpkins CE, Phillips M, Desai A, Collins V, Reeb B, Kraus E, Rabb H, Leffell MS, Warren DS: Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 294: , Montgomery RA, Gentry SE, Marks WH, Warren DS, Hiller J, Houp J, Zachary AA, Melancon JK, Maley WR, Rabb H, Simpkins C, Segev DL: Domino paired kidney donation: A strategy to make best use of live non-directed donation. Lancet 368: , Roth AE, Sonmez T, Unver MU, Delmonico FL, Saidman SL: Utilizing list exchange and nondirected donation through chain paired kidney donations. Am J Transplant 6: , de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Weimar W, Claas, FH: A flexible national living donor kidney exchange program taking advantage of a central histocompatibility laboratory: the Dutch model. Clin Transpl 69 73, Delmonico FL, Morrissey PE, Lipkowitz GS, Stoff JS, Himmelfarb J, Harmon W, Pavlakis M, Mah H, Goguen J, Luskin R, Milford E, Basadonna G, Chobanian M, Bouthot B, Lorber M, Rohrer RJ: Donor kidney exchanges. Am J Transplant 4: , Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, Cosio FG, Gandhi MJ, Kremers W, Stegall MD: Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 10: , Gebel HM, Bray RA, Nickerson P: Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 3: , Shehata N, Palda VA, Meyer RM, Blydt-Hansen TD, Campbell P, Cardella C, Martin S, Nickerson P, Peltekian K, Ross H, Waddell TK, West L, Anderson D, Freedman J, Hume H: The use of immunoglobulin therapy for patients undergoing solid organ transplantation: An evidence-based practice guideline. Transfus Med Rev 24 Suppl 1: S7 S27, Peraldi MN, Akposso K, Haymann JP, Flahaut A, Marlin C, Rondeau E, Sraer JD: Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 62: , 1996
6 2046 Clinical Journal of the American Society of Nephrology 22. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 15: , Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S: A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6: , Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk- Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M: Positive cross-match living donor kidney transplantation: Longerterm outcomes. Am J Transplant 9: , Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G: ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: A 3-year follow-up. Transplantation 85: , Tanabe K: Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 84: S4 S7, 2007 Received: March 28, 2011 Accepted: April 21, 2011 Published online ahead of print. Publication date available at
Strategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationDesensitization in HLA-Incompatible Kidney Recipients and Survival
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Desensitization in HLA-Incompatible Kidney Recipients and Survival Robert A. Montgomery, M.D., D.Phil., Bonnie E. Lonze, M.D., Ph.D.,
More informationSingle-Center Kidney Paired Donation: The Methodist San Antonio Experience
American Journal of Transplantation 2012; 12: 2125 2132 Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2012.04070.x
More informationLiving Kidney Donors Ages 70 and Older: Recipient and Donor Outcomes
Article Living Kidney Donors Ages 70 and Older: Recipient and Donor Outcomes Jonathan C. Berger,* Abimereki D. Muzaale,* Nathan James,* Mohammed Hoque, Jacqueline M. Garonzik Wang,* Robert A. Montgomery,*
More informationPeter Chang,* Jagbir Gill,* James Dong,* Caren Rose,* Howard Yan,* David Landsberg,* Edward H. Cole, and John S. Gill*
Article Living Donor Age and Kidney Allograft Half-Life: Implications for Living Donor Paired Exchange Programs Peter Chang,* Jagbir Gill,* James Dong,* Caren Rose,* Howard Yan,* David Landsberg,* Edward
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationTransfusion support in Transplantation
Transfusion support in Transplantation Patricia Campbell University of Alberta Hospitals University of Alberta Objectives UofA transplant programs What we do and why? HLA and ABO incompatible transplants
More informationRENAL TRANSPLANTATION HAS
ORIGINAL CONTRIBUTION Kidney Paired Donation and Optimizing the Use of Live Donor Organs Dorry L. Segev, MD Sommer E. Gentry, MS Daniel S. Warren, PhD Brigitte Reeb, MFA Robert A. Montgomery, MD, DPhil
More informationKidney Transplantation in Sensitized Recipients; A Single Center Experience
J Korean Med Sci 2009; 24 (Suppl 1): S143-7 ISSN 1011-8934 DOI: 10.3346/jkms.2009.24.S1.S143 Copyright The Korean Academy of Medical Sciences Kidney Transplantation in Sensitized Recipients; A Single Center
More informationShould red cells be matched for transfusions to patients listed for renal transplantation?
Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched
More informationTreatment Update of Sensitized Pediatric Kidney Transplant Recipients: A Review
RevIew Treatment Update of Sensitized Pediatric Kidney Transplant Recipients: A Review Hasan Otukesh, 1 Rozita Hoseini, 2 Nahid Rahimzadeh 3 Abstract Sensitization of recipients is an increasing problem
More informationThe Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis
American Journal of Transplantation 2017; 17: 3123 3130 Wiley Periodicals Inc. 2017 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.14392 The Incremental
More informationQuantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b
Quantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b a John Hopkins University, Immunogenetics Laboratory, Baltimore, Maryland and b Cedars-Sinai
More informationUtilizing List Exchange and Nondirected Donation through Chain Paired Kidney Donations
Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2006.01515.x Utilizing
More informationKidney paired donation in the presence of donor-specific antibodies
http://www.kidney-international.org & 2013 International Society of Nephrology clinical investigation Kidney paired donation in the presence of donor-specific antibodies Jeremy M. Blumberg 1, Hans A. Gritsch
More informationABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR
ABO ABO ABO ABO ABO ABO ABO ABO ABO ABO.. ABO ABO. ABO. ABO ABO Key words ABO ABO A B antibody-mediated rejection, AMR Alexandre ABO double filtration plasmapheresis, DFPP ABO ABO n ABO n p-value R.....
More informationSuccessful Renal Transplantation with Desensitization in Highly Sensitized Patients: A Single Center Experience
J Korean Med Sci 29; 24 (Suppl 1): S148-55 ISSN 111-8934 DOI: 1.3346/jkms.29.24.S1.S148 Copyright The Korean Academy of Medical Sciences Successful Renal Transplantation with Desensitization in Highly
More informationIn the past 15 years the number of kidney
The Role of ABO-Incompatible Living Donors in Kidney Transplantation: State of the Art James Thielke, PharmD,* Bruce Kaplan, MD, and Enrico Benedetti, MD, FACS Summary: In the past, ABO incompatibility
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationEven in this era of efficient immunosuppression, a positive
OVERVIEW Enhanced Kidney Allocation to Highly Sensitized Patients by the Acceptable Mismatch Program Frans H. J. Claas, 1 Axel Rahmel, 2 and IIias I. N. Doxiadis 1 Even in this era of efficient immunosuppression,
More informationSurvival Benefit with Kidney Transplants from HLA-Incompatible Live Donors
The new england journal of medicine Original Article Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors B.J. Orandi, X. Luo, A.B. Massie, J.M. Garonzik Wang, B.E. Lonze, R. Ahmed,
More informationLiving Donor Paired Exchange (LDPE)
Living Donor Paired Exchange (LDPE) Why do we need Living Donation? 3,796 patients waiting for an organ transplant 2,679 (71%) waiting for a kidney transplant 249 people died while waiting for an organ
More informationTo date, 209 patients in the United States have undergone
FORUM Utilization and Outcomes of Kidney Paired Donation in the United States Dorry L. Segev, Lauren M. Kucirka, Sommer E. Gentry, and Robert A. Montgomery Background. Kidney paired donation (KPD) offers
More informationABO Antibody Titer and Risk of Antibody-Mediated Rejection in ABO-Incompatible Renal Transplantation
American Journal of Transplantation 2010; 10: 1247 1253 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationDesensitization for solid organ and hematopoietic stem cell transplantation
Andrea A. Zachary Mary S. Leffell Desensitization for solid organ and hematopoietic stem cell transplantation Authors address Andrea A. 1 Zachary, Mary S. Leffell 1 1 Department of Medicine, Division of
More informationAntihuman leukocyte antigen (HLA) antibodies can be
Antihuman Leukocyte Antigen Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches Ibrahim Batal, MD; Adriana Zeevi, PhD; John
More informationVirtual Crossmatch in Kidney Transplantation
Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU 2018.11.21 All transplant candidates are screened to determine the degree of humoral
More information6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?
6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationPaired Donation. Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle. Cambridge University NHS Hospitals NHS Foundation trust
Paired Donation Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle Cambridge University NHS Hospitals NHS Foundation trust Showing a preference 1860 John Calcott Horsley UK Living Donor kidney transplant
More informationPosttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients
Trends in Transplant. 2014;8:3-9 Gregor Bartel, Georg A. Böhmig: Alloantibodies and Graft Function Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Gregor Bartel
More informationTransplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation
AACC Professional Course BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation J. Ryan
More informationORIGINAL ARTICLE. Kidney Transplant Chains Amplify Benefit of Nondirected Donors
OIGINAL ATICLE Kidney Transplant Chains Amplify Benefit of Nondirected Donors Marc L. Melcher, MD, PhD; Jeffrey L. Veale, MD; Basit Javaid, MD; David B. Leeser, MD; Connie L. Davis, MD; Garet Hil, MBA;
More informationEculizumab chez les receveurs de greffe rénal à haut risque immunologique. Mark D. Stegall Mayo Clinic, Rochester, MN
Eculizumab chez les receveurs de greffe rénal à haut risque immunologique Mark D. Stegall Mayo Clinic, Rochester, MN Disclosure. Dr Mark Stegall. Institution : Mayo Clinic, Rochester. Research contracts
More informationIncreasing the Opportunity of Live Kidney Donation by Matching for Two and Three Way Exchanges
M Munich Personal RePEc Archive Increasing the Opportunity of Live Kidney Donation by Matching for Two and Three Way Exchanges Susan L. Saidman and Alvin E. Roth and Tayfun Sonmez and M. Utku Unver and
More informationExtending options for highly sensitized patients to receive a suitable kidney graft Ilias IN Doxiadis 1, Rene J Duquesnoy 2 and Frans HJ Claas 1
Extending options for highly sensitized patients to receive a suitable kidney graft Ilias IN Doxiadis 1, Rene J Duquesnoy 2 and Frans HJ Claas 1 Highly sensitized patients (anti-hla) on the kidney waiting
More informationRituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
The new england journal of medicine original article Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation Ashley A. Vo, Pharm.D., Marina Lukovsky, Pharm.D., Mieko
More informationQuantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
Wiley Periodicals Inc. C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons Quantification of the Early Risk of Death in Elderly Kidney Transplant Recipients
More informationTransplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
More informationTransfusion and Apheresis Science
Transfusion and Apheresis Science 43 (2010) 231 235 Contents lists available at ScienceDirect Transfusion and Apheresis Science journal homepage: www.elsevier.com/locate/transci Isoagglutinin adsorption
More informationIn-Depth Review. Desensitization Protocols and Their Outcome
In-Depth Review Desensitization Protocols and Their Outcome Kwaku Marfo,* Amy Lu,* Min Ling* and Enver Akalin* Summary In the last decade, transplantation across previously incompatible barriers has increasingly
More informationKidney vs. Liver: Where are We Really with Allocation in Kidney Transplantation?
Kidney vs. Liver: Where are We Really with Allocation in Kidney Transplantation? Mark D. Stegall,, MD Chair, UNOS/OPTN Kidney Allocation Review Subcommittee Different Allocation Factors Liver Wait list
More informationRevIeWS. Sensitized renal transplant recipients: current protocols and future directions. James Gloor and Mark D. Stegall
RevIeWS Sensitized renal transplant recipients: current protocols and future directions James Gloor and Mark D. Stegall Abstract The identification of suitable donor kidneys for transplant candidates with
More informationClinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
More informationCASE REPORT ABSTRACT INTRODUCTION. Renal transplant was successfully performed after conversion.
CASE REPORT Port J Nephrol Hypert 2007; 21(1): 41-47 Successful live donor kidney transplant in a hypersensitised patient with positive cross-match. A case report and a review of the effectiveness of desensitisation
More informationABO-incompatible kidney transplantation in elderly patients over 60 years of age
Int Urol Nephrol (2012) 44:1563 1570 DOI 10.1007/s11255-012-0231-z NEPHROLOGY - ORIGINAL PAPER ABO-incompatible kidney transplantation in elderly patients over 60 years of age Junji Uchida Tomoaki Iwai
More informationDiagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service
Diagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service 1. Introduction Transplantation offers better survival and quality
More informationA POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION
THE NEW KIDNEY ALLOCATION SYSTEM: A POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION Paul Warner, PhD, D(ABHI) Director, HLA/Immunogenetics Laboratory Bloodworks Northwest Seattle, Washington Disclosure
More informationApproach to Kidney Transplant in Sensitized Potential Transplant Recipients
RevIew Approach to Kidney Transplant in Sensitized Potential Transplant Recipients Antoine Barbari, Souodod Abbas, Mahassen Jaafar Abstract More than one-third of patients on waiting lists for kidney transplant
More informationSolid Organ Transplant
Solid Organ Transplant Lee R. Goldberg, MD, MPH, FACC Associate Professor of Medicine Medical Director, Heart Failure and CardiacTransplant Program University of Pennsylvania Disclosures Thoratec Consulting
More informationRenal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches
Transplant International ISSN 0934-0874 ORIGINAL ARTICLE Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches Kyu Ha Huh,
More informationThe New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health
The New Kidney Allocation System: What You Need to Know Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health ~6% of patients die each year on the deceased donor waiting
More informationA Case of Desensitization, Transplantation, and Allograft Dysfunction
Clinical Conference A Case of Desensitization, Transplantation, and Allograft Dysfunction Colm Magee,* Michael Clarkson, and Helmut Rennke *Department of Nephrology, Beaumont Hospital, Dublin, Ireland;
More informationInfectious Complications in Living-Donor Kidney Transplant Recipients Undergoing Multi-Modal Desensitization
SURGICAL INFECTIONS Volume 15, Number 3, 2014 ª Mary Ann Liebert, Inc. DOI: 10.1089/sur.2012.231 Surgical Infection Society Articles Infectious Complications in Living-Donor Kidney Transplant Recipients
More informationTreatment of Chronic Antibody Mediated Rejection
Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech
More informationBlood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT
Blood Group Incompatible Renal Transplantation and Apheresis Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT Background There is growing interest in transplantation across the
More informationMORTALITY IN PATIENTS ON DIALYSIS AND TRANSPLANT RECIPIENTS
MORTALITY IN PATIENTS ON DIALYSIS AND TRANSPLANT RECIPIENTS COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS, PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION, AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT
More informationOriginal Effective Date: 02/02/15. Subject: Intravenous Immune Globulin (IVIg) Therapy for Solid Organ Transplant. Policy Number: MCP-237
Subject: Intravenous Immune Globulin (IVIg) Therapy for Solid Organ Transplant Policy Number: MCP-237 Original Effective Date: 02/02/15 Revision Date(s): Review Date(s): 12/15/2016; 6/22/2017 DISCLAIMER
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
More informationNearly half of a million individuals in the United
Access to Kidney Transplantation among the Elderly in the United States: A Glass Half Full, not Half Empty Elke S. Schaeffner,* Caren Rose, and John S. Gill *Division of Nephrology, Charité University
More informationLiver Sharing and Organ Procurement Organization Performance
LIVER TRANSPLANTATION 21:293 299, 2015 ORIGINAL ARTICLE Liver Sharing and Organ Procurement Organization Performance Sommer E. Gentry, 1,2 Eric K. H. Chow, 1 Allan Massie, 1,3 Xun Luo, 1 David Zaun, 4
More informationLiving-donor kidney transplantation across ABO barriers: the first case in Thailand
Asian Biomedicine Vol. 3 No. 5 October 2009; 525-529 Clinical report Living-donor kidney transplantation across ABO barriers: the first case in Thailand Yingyos Avihingsanon a, Natavudh Townamchai a, Supanit
More informationJ Am Soc Nephrol 14: , 2003
J Am Soc Nephrol 14: 208 213, 2003 Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis
More informationApproach to the Highly Sensitized Kidney Transplant Candidate
CJASN epress. Published on February 25, 2016 as doi: 10.2215/CJN.05930615 Attending Rounds Approach to the Highly Sensitized Kidney Transplant Candidate Douglas S. Keith and Gayle M. Vranic Abstract For
More information9/30/2016. Chris E. Freise, MD Professor of Surgery UCSF Transplant Division
Chris E. Freise, MD Professor of Surgery UCSF Transplant Division Clear advantages over deceased donation for kidney transplant Shorter wait times Better short and long term function Improved graft half-life
More informationHoward M. Gebel, Omar Moussa, David D. Eckels, Robert A. Bray
Accepted Manuscript Donor Reactive HLA Antibodies in Renal Allograft Recipients: Considerations, Complications and Conundrums Howard M. Gebel, Omar Moussa, David D. Eckels, Robert A. Bray PII: S0198-8859(09)00101-3
More informationLiving-Donor Kidney Transplant in T-Cell and B-Cell Flow Cytometry Crossmatch-Positive Patients
ARTICLe Living-Donor Kidney Transplant in T-Cell and B-Cell Flow Cytometry Crossmatch-Positive Patients Soushi Terasaka, 1 Hidehisa Kitada, 1,3 Yasuhiro Okabe, 1 Sayako Kawanami, 1 Hiroshi Noguchi, 1 Kyoko
More informationORIGINAL ARTICLE. awaiting kidney transplantation has continued
ORIGINAL ARTICLE Outcomes of Renal Transplants From Centers for Disease Control and Prevention High-Risk Donors With Prospective Recipient Viral Testing A Single-Center Experience Bonnie E. Lonze, MD,
More informationAssociation of Kidney Transplantation with Survival in Patients with Long Dialysis Exposure
Article Association of Kidney Transplantation with Survival in Patients with Long Dialysis Exposure Caren Rose,* Jagbir Gill,* and John S. Gill* Abstract Background and objectives Evidence that kidney
More informationArticle. Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous Immunoglobulin
Article Infectious Complications in Kidney-Transplant Recipients Desensitized with Rituximab and Intravenous Immunoglobulin Joseph Kahwaji,* Aditi Sinha, Mieko Toyoda, Shili Ge, Nancy Reinsmoen, Kai Cao,
More informationPediatric Transplantation DOI: /j x
Pediatr Transplantation 2007: 11: 77 81 Copyright Ó 2007 Blackwell Munksgaard Pediatric Transplantation DOI: 10.1111/j.1399-3046.2006.00617.x Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker
More informationPancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
More informationABO mismatched Renal Transplants
ABO mismatched Renal Transplants Nicos Kessaris Renal Transplant Surgeon St George s Hospital, London 7 th March 2012 Why? Protocol Risks Experience abroad Experience in UK Experience at St George s Conclusions
More informationHong Kong Journal Nephrol of 2000;(2): Nephrology 2000;2(2): BR HAWKINS ORIGINAL A R T I C L E A point score system for allocating cadaver
Hong Kong Journal Nephrol of 2000;(2):79-83. Nephrology 2000;2(2):79-83. ORIGINAL A R T I C L E A point score system for allocating cadaveric kidneys for transplantation based on patient age, waiting time
More informationThe Acceptable Mismatch program of Eurotransplant.
The Acceptable Mismatch program of Eurotransplant. Frans Claas Leiden University Medical Center Eurotransplant Reference Laboratory Leiden, the Netherlands. Hinterzarten, December 7, 2013 Main problem
More information23/10/2017. Panel Reactive Antibodies and Crossmatch by Flow Cytometry. Antibodies against. Renal transplantation. Antibody mediated rejection (AMR)
Renal transplantation Panel Reactive Antibodies and Crossmatch by Flow Cytometry Katherina Psarra Immunology Histocompatibility Dept Evangelismos Hospital Athens, Greece In spite of the enormous progress
More informationHHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 August 01.
A closer look at rituximab induction on HLA antibody rebound following HLA incompatible kidney transplantation Annette M. Jackson, PhD 1,3, Edward S. Kraus, MD 1, Babak J. Orandi, MD PhD 2, Dorry L. Segev,
More informationThe principal goals of kidney transplantation are to improve
Is Kidney Transplantation for Everyone? The Example of the Older Dialysis Patient Greg A. Knoll Division of Nephrology, Kidney Research Centre, and the Clinical Epidemiology Program, Ottawa Hospital Research
More informationLong-Term Renal Allograft Survival in the United States: A Critical Reappraisal
American Journal of Transplantation 2011; 11: 450 462 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant
More informationShould Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?
American Journal of Transplantation 2008; 8: 2056 2061 Wiley Periodicals Inc. C 2008 The Authors Journal compilation C 2008 The American Society of Transplantation and the American Society of Transplant
More informationABO INCOMPATILIBITY AND TRANSPLANTATION
ABO INCOMPATILIBITY AND TRANSPLANTATION Aleksandar Mijovic Consultant Haematologist/Senior Lecturer King s College Hospital/NHS Blood and Transplant London, UK RTC Edu Meeting May 2017 ABO antigens Expressed
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More informationEarly Changes in Kidney Distribution under the New Allocation System
Early Changes in Kidney Distribution under the New Allocation System Allan B. Massie,* Xun Luo,* Bonnie E. Lonze,* Niraj M. Desai,* Adam W. Bingaman, Matthew Cooper, and Dorry L. Segev* *Department of
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationKPD transplants. Dutch Experience. Korean experience. NEAD chain
KPD transplants David Serur, MD Rogosin, NYP Weill Cornell May 2013 NEAD chain Milestones in Paired Exchange Rees, NEJM, 2009 Korean experience Single center Not computer matched 129 transplants over 11
More informationTable S1. Clinical outcomes of the acceptable mismatch allocation model.
Table S1. Clinical outcomes of the acceptable mismatch allocation model. Recipient Age PRA Waiting Time (months) HLA mismatch (A/B/DR) HLAMatchmaker acceptable mismatch (years) (%) Actual Simulation Change
More informationPrevalence and Outcomes of Multiple-Listing for Cadaveric Kidney and Liver Transplantation
American Journal of Transplantation 24; 4: 94 1 Blackwell Munksgaard Copyright C Blackwell Munksgaard 23 doi: 1.146/j.16-6135.23.282.x Prevalence and Outcomes of Multiple-Listing for Cadaveric Kidney and
More informationThe right organ for the right recipient: the Ninth Annual American Society of Transplant SurgeonsÕ State-of-the-Art Winter Symposium
Clin Transplant 2011: 25: E592 E598 DOI: 10.1111/j.1399-0012.2011.01513.x ª 2011 John Wiley & Sons A/S. The right organ for the right recipient: the Ninth Annual American Society of Transplant SurgeonsÕ
More informationShipping living donor kidneys and transplant recipient outcomes
Received: 8 June 2017 Revised: 20 October 2017 Accepted: 13 November 2017 DOI: 10.1111/ajt.14597 ORIGINAL ARTICLE Shipping living donor kidneys and transplant recipient outcomes Eric Treat 1 Eric K. H.
More informationNHSBT Board July Update on UK Living Kidney Sharing Scheme
1. Status Public 2. Executive Summary NHSBT Board July 27 2017 Update on UK Living Kidney Sharing Scheme This paper provides an update on activity and plans for the UK Living Kidney Sharing Scheme (UKLKSS),
More informationDonor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative Renal Transplants
Available online at www.annclinlabsci.org 330 Annals of Clinical & Laboratory Science, vol. 40, no. 4, 2010 Donor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative
More informationThe Kidney Allocation System Changed in a Substantive Way on December 5, Your Patients Have Been, and Will Be, Affected by These Changes
The Kidney Allocation System Changed in a Substantive Way on December 5, 2014 Your Patients Have Been, and Will Be, Affected by These Changes 1 The New Kidney Allocation System Terms of Importance Pediatric
More informationOxford Transplant Centre. Live donor kidney transplantation what if we are not a match?
Oxford Transplant Centre Live donor kidney transplantation what if we are not a match? page 2 You will already have been provided with information about different types of kidney transplant and the tests
More informationKidney Exchange: Past, Present, and Potential Future
1/42 Kidney Exchange: Past, Present, and Potential Future Tayfun Sönmez, Boston College The Eighth Biennial Conference on Economic Design July 25-27, 2013, Lund, Sweden Lund University, School of Economics
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationDonor Kidney Exchanges
American Journal of Transplantation 2004; 4: 1628 1634 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00572.x Donor Kidney Exchanges Francis L. Delmonico a,, Paul
More informationOrgan transplantation in Bulgaria
Cell Tissue Banking (28) 9:337 342 DOI 1.17/s1561-7-935-2 Organ transplantation in Bulgaria Elissaveta Naumova Æ Petar Panchev Æ Pencho J. Simeonov Æ Anastassia Mihaylova Æ Kalina Penkova Æ Petia Boneva
More information